Pneumology - Original Articles

Characterizing non-cystic fibrosis bronchiectasis: spirometry indices and disease burden by FACED score

Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 7 May 2026
0
Views
0
Downloads

Authors

This study aimed to characterize the clinical, radiological, and severity profile by spirometry indices and evaluate the clinical and structural disease burden stratified by FACED [FEV1% predicted (F), age (A), chronic colonization by Pseudomonas aeruginosa (C), extension of the disease by radiological assessment (E), and dyspnea (D)] severity in patients with non-cystic fibrosis (CF) bronchiectasis. A retrospective review of 125 patients with non-CF bronchiectasis who underwent a pulmonary lung function test at the Aga Khan University Hospital (Karachi, Pakistan) was conducted. Spirometry patterns were normal, obstructive, restrictive, and mixed. FACED classifications were mild (0-2) and moderate-severe disease (≥3). Pseudomonas aeruginosa was found in 26.40%. Obstructive ventilatory disorder (54.40%) was the most frequent finding. Symptom duration of >10 years was relatively frequent in the obstructive group (34.69%; p=0.012). Moderate-to-severe disease (FACED≥3) was most prevalent in the obstructive pattern (60.29%; p=0.012). Patients with moderate-to-severe disease more frequently reported longer symptom duration compared with those with mild disease (p=0.015). Non-CF bronchiectasis patients with obstructive ventilatory disease may present with a longer duration of symptoms and disease severity. Patients with moderate-severe disease had longer symptom duration, with trends towards higher lung parenchymal injury (residual fibrosis on high-resolution computed tomography) and hospitalization due to respiratory infection.

Downloads

Download data is not yet available.

Citations

O’Donnell AE. Bronchiectasis update. Curr Opin Infect Dis 2018;31:194-8.
O’Donnell AE. Bronchiectasis—a clinical review. N Engl J Med 2022;387:533-45.
Magis-Escurra C, Reijers MH. Bronchiectasis. BMJ Clin Evid 2015;2015:1507.
Barker AF. Bronchiectasis. N Engl J Med 2002;346:1383-93.
Perea L, Faner R, Chalmers JD, Sibila O. Pathophysiology and genomics of bronchiectasis. Eur Respir Rev 2024;33:240055.
King PT, Holdsworth SR, Freezer NJ, et al. Characterisation of the onset and presenting clinical features of adult bronchiectasis. Respir Med 2006;100:2183-9.
Dodd JD, Lavelle LP, Fabre A, Brady D. Imaging in cystic fibrosis and non–cystic fibrosis bronchiectasis. Semin Respir Crit Care Med 2015;36:194-206.
Tiddens HA, Meerburg JJ, van der Eerden MM, Ciet P. The radiological diagnosis of bronchiectasis: what's in a name? Eur Respir Rev 2020;29:1190120.
Keir HR, Chalmers JD. Pathophysiology of bronchiectasis. Semin Respir Crit Care Med 2021;42:499-512.
Gao Yh, Guan Wj, Liu Sx, et al. Aetiology of bronchiectasis in adults: a systematic literature review. Respirology 2016;21:1376-83.
Radovanovic D, Santus P, Blasi F, et al. A comprehensive approach to lung function in bronchiectasis. Respir Med 2018;145:120-9.
Kim S-H, Yang B, Yoo JY, et al. Clinical characteristics, radiological features, and disease severity of bronchiectasis according to the spirometric pattern. Sci Rep 2022;12:13167.
Martínez-García M, de Gracia J, Vendrell Relat M, et al. Multidimensional approach to non-cystic fibrosis bronchiectasis: the FACED score. Eur Respir J 2014;43:1357-67.
AKUH. The Aga Khan University Hospitals. Available from: https://hospitals.aku.edu/Pages/default.aspx.
Graham BL, Steenbruggen I, Miller MR, et al. Standardization of spirometry 2019 update. An official American Thoracic Society and European Respiratory Society technical statement. Am J Respir Crit Care Med 2019;200:e70-88.
Murray PR, Washington JA. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc 1975;50:339-44.
Choi H, Yang B, Kim YJ, et al. Increased mortality in patients with non cystic fibrosis bronchiectasis with respiratory comorbidities. Sci Rep 2021;11:7126.
Alam MA, Mangapuram P, Fredrick FC, et al. Bronchiectasis-COPD overlap syndrome: a comprehensive review of its pathophysiology and potential cardiovascular implications. Ther Adv Pulm Crit Care Med 2024;19:29768675241300808.
Singh P, Katoch CDS, Vardhan V, et al. Functional impairment in bronchiectasis: Spirometry parameters versus St. George's Respiratory Questionnaire scores: any co-relation? Lung India 2021;38:545-51.
Gallucci M, Candela E, Di Palmo E, et al. Non-cystic fibrosis bronchiectasis in pediatric age: a case series in a metropolitan area of northern Italy. Children 2022;9:1420.
Sevgili S, Hasanoğlu HC, Karalezli A, Er M. Bronchial reversibility in the patients with bronchiectasis. Tuberk Toraks 2009;57:38-47.
Khalid M, Al Mandeel B, Bazarbashi M, et al. Common pulmonary function test findings and response to inhaled bronchodilators (salbutamol) in patients with postinfectious, noncystic fibrosis, bronchiectasis in KINGDOM of Saudi Arabia. Chest 2000;118:196S.
McDonnell MJ, Aliberti S, Goeminne PC, et al. Comorbidities and the risk of mortality in patients with bronchiectasis: an international multicentre cohort study. Lancet Respir Med 2016;4:969-79.
Goeminne P, Nawrot TS, Ruttens D, et al. Mortality in non-cystic fibrosis bronchiectasis: a prospective cohort analysis. Respir Med 2014;108:287-96.
Martínez-García MÁ, Soler-Cataluña JJ, Sanz YD, et al. Factors associated with bronchiectasis in patients with COPD. Chest 2011;140:1130-7.
Navaratnam V, Millett ER, Hurst JR, et al. Bronchiectasis and the risk of cardiovascular disease: a population-based study. Thorax 2017;72:161-6.
Loebinger M, Wells A, Hansell D, et al. Mortality in bronchiectasis: a long-term study assessing the factors influencing survival. Eur Respir J 2009;34:843-9.
Keistinen T, Saynajakangas O, Tuuponen T, Kivela S. Bronchiectasis: an orphan disease with a poorly-understood prognosis. Eur Respir J 1997;10:2784-7.
Wang L, Wang J, Zhao G, Li J. Prevalence of bronchiectasis in adults: a meta-analysis. BMC Public Health 2024;24:2675.
Beckeringh NI, Rutjes NW, van Schuppen J, Kuijpers TW. Noncystic fibrosis bronchiectasis: evaluation of an extensive diagnostic protocol in determining pediatric lung disease etiology. Pediatr Allergy Immunol Pulmonol 2019;32:155-62.
Kim H-Y, Kwon J-W, Seo J, et al. Bronchiectasis in children: 10-year experience at a single institution. Allergy Asthma Immunol Res 2011;3:39-45.
McDonnell MJ, Jary HR, Perry A, et al. Non cystic fibrosis bronchiectasis: a longitudinal retrospective observational cohort study of Pseudomonas persistence and resistance. Respir Med 2015;109:716-26.
Shahid S, bin Abdul Jabbar A, Wagley A, et al. Non-cystic fibrosis bronchiectasis: a retrospective review of clinical, radiological, microbiological and lung function profile at a tertiary care center of a low-middle-income country. Monaldi Arch Chest Dis 2023;94:2718.
Shafiq I, Wahla AS, Uzbeck MH, et al. Etiology and clinical characteristics of a non-cystic fibrosis bronchiectasis cohort in a middle eastern population. BMC Pulm Med 2023;23:250.

Ethics Approval

Given the retrospective nature of the study, a waiver of ethics approval and informed consent was obtained from the Ethics Review Committee (ERC) of the Aga Khan University (ERC #2022-7529-21827). The study was performed in accordance with the ethical standards outlined in the 1964 Declaration of Helsinki and its future amendments.

How to Cite



“Characterizing Non-Cystic Fibrosis Bronchiectasis: Spirometry Indices and Disease Burden by FACED Score”. 2026. Monaldi Archives for Chest Disease, May. https://doi.org/10.4081/monaldi.2026.3920.